"Time sweet time": circadian characterization of galectin-1 null mice.
BACKGROUND
Recent evidence suggests a two-way interaction between the immune and circadian systems. Circadian control of immune factors, as well as the effect of immunological variables on circadian rhythms, might be key elements in both physiological and pathological responses to the environment. Among these relevant factors, galectin-1 is a member of a family of evolutionarily-conserved glycan-binding proteins with both extracellular and intracellular effects, playing important roles in immune cell processes and inflammatory responses. Many of these actions have been studied through the use of mice with a null mutation in the galectin-1 (Lgals1) gene. To further analyze the role of endogenous galectin-1 in vivo, we aimed to characterize the circadian behavior of galectin-1 null (Lgals1-/-) mice.


METHODS
We analyzed wheel-running activity in light-dark conditions, constant darkness, phase responses to light pulses (LP) at circadian time 15, and reentrainment to 6 hour shifts in light-dark schedule in wild-type (WT) and Lgals1-/- mice.


RESULTS
We found significant differences in free-running period, which was longer in mutant than in WT mice (24.02 vs 23.57 h, p < 0.005), phase delays in response to LP (2.92 vs 1.90 circadian h, p < 0.05), and also in alpha (14.88 vs. 12.35 circadian h, p < 0.05).


CONCLUSIONS
Given the effect of a null mutation on circadian period and entrainment, we indicate that galectin-1 could be involved in the regulation of murine circadian rhythmicity. This is the first study implicating galectin-1 in the mammalian circadian system.
Casiraghi
Leandro P
LP
Departamento de Ciencia y Tecnología, Universidad Nacional de Quilmes/CONICET, Argentina. dgolombek@unq.edu.ar.
Croci
Diego O
DO
Poirier
Francoise
F
Rabinovich
Gabriel A
GA
Golombek
Diego A
DA
Development. 1993 Dec;119(4):1229-36
8306885
Cancer Cell. 2004 Mar;5(3):241-51
15050916
J Mol Neurosci. 2002 Feb-Apr;18(1-2):105-9
11931340
Nat Rev Immunol. 2009 May;9(5):338-52
19365409
Nat Med. 2007 Dec;13(12):1450-7
18026113
Brain Res Dev Brain Res. 1999 Nov 18;117(2):171-8
10567735
Glycobiology. 2006 Nov;16(11):137R-157R
16840800
Cell Mol Biol Lett. 2009;14(1):128-38
18850073
Proc Soc Exp Biol Med. 1960 Jan;103:142-4
14398944
Nat Rev Cancer. 2005 Jan;5(1):29-41
15630413
Neurosci Lett. 2004 Mar 18;358(1):9-12
15016422
J Neurobiol. 2000 Dec;45(4):195-206
11077424
Cell Death Differ. 2009 Mar;16(3):417-27
19008923
Nat Immunol. 2009 Sep;10(9):981-91
19668220
Chronobiol Int. 1999 Sep;16(5):581-622
10513884
Shock. 1999 Aug;12(2):118-26
10446892
Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12843-8
17646651
Physiol Rev. 2010 Jul;90(3):1063-102
20664079
Nat Immunol. 2008 Jun;9(6):593-601
18490910
J Biol Rhythms. 2008 Apr;23(2):150-9
18375864
Brain Res. 2008 Sep 26;1232:104-12
18703032
Infect Immun. 1999 Dec;67(12):6603-10
10569781
J Neurosci Res. 2006 Nov 15;84(7):1521-7
16955486
J Immunol. 1997 Jun 1;158(11):5163-8
9164932
Int Arch Allergy Immunol. 2005 Apr;136(4):385-400
15775687
Chronobiol Int. 2009 Oct;26(7):1430-42
19916840
J Neurosci. 2005 Jan 12;25(2):404-8
15647483
Neuroscience. 2003;118(1):253-61
12676155
Expert Rev Mol Med. 2008 Jun 13;10:e17
18549522
J Neurochem. 2007 Jun;101(5):1214-23
17403142
Curr Drug Targets. 2005 Jun;6(4):419-25
16026260
Dev Biol. 1996 Oct 10;179(1):274-87
8873770
Exp Neurol. 2007 Oct;207(2):302-13
17706645
Langenbecks Arch Surg. 2001 Mar;386(2):132-40
11374046
Nat Immunol. 2007 Aug;8(8):825-34
17589510
Nat Neurosci. 2007 Jun;10(6):712-9
17486104
Neurosci Lett. 2000 Jul 21;288(3):228-30
10889349
Eur Surg Res. 2002 Jan-Apr;34(1-2):22-9
11867897
Neuroreport. 1994 Feb 24;5(6):712-4
8199344
Proc Natl Acad Sci U S A. 2006 May 2;103(18):7112-7
16636291
J Neuroimmunol. 2005 Mar;160(1-2):102-9
15710463
Eur J Neurosci. 2006 Dec;24(11):3017-25
17156363